Amylyx Pharmaceuticals (AMLX) Share-based Compensation (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Share-based Compensation of $12.3 million for Q1 2026, up 79.98% year-over-year from $6.8 million in Q1 2025, and up 92.58% quarter-over-quarter from $6.4 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Share-based Compensation (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Share-based Compensation history runs 6 years deep, the most recent figure standing at $12.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 79.98% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (down 58.93% YoY), while the FY2025 annual figure was $27.6 million, down 16.32% from the prior year.
- Share-based Compensation for Q1 2026 stood at $12.3 million, up from $6.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $23.9 million in Q3 2025, with the low at $5.0 million in Q1 2022.
- The 5-year median for Share-based Compensation is $7.5 million (2023), against an average of $9.4 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 1435.84% in 2022, then slumped 43.1% in 2023.
- Amylyx Pharmaceuticals' Share-based Compensation stood at $16.8 million in 2022, then sank by 43.1% to $9.5 million in 2023, then dropped by 29.3% to $6.7 million in 2024, then decreased by 5.27% to $6.4 million in 2025, then surged by 92.58% to $12.3 million in 2026.
- Business Quant data shows AMLX's Share-based Compensation at $12.3 million in Q1 2026, $6.4 million in Q4 2025, and $23.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.28 Bn | 4.28 Bn | - | 8.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.32 Mn |
| Jun 30, 2026 | 8.32 Mn |
| Mar 31, 2026 | 12.30 Mn |
| Mar 31, 2026 | 12.30 Mn |
| Dec 31, 2025 | 6.39 Mn |
| Dec 31, 2025 | 6.39 Mn |
| Sep 30, 2025 | 23.93 Mn |
| Sep 30, 2025 | 23.93 Mn |
| Jun 30, 2025 | 7.35 Mn |
| Jun 30, 2025 | 7.35 Mn |
| Mar 31, 2025 | 6.83 Mn |
| Mar 31, 2025 | 6.83 Mn |
| Dec 31, 2024 | 6.74 Mn |
| Dec 31, 2024 | 6.74 Mn |
| Sep 30, 2024 | 6.80 Mn |
| Sep 30, 2024 | 6.80 Mn |
| Jun 30, 2024 | 9.57 Mn |
| Jun 30, 2024 | 9.57 Mn |
| Mar 31, 2024 | 9.92 Mn |
| Mar 31, 2024 | 9.92 Mn |